PEGylation, successful approach to drug delivery

被引：1902

作者：

Veronese, FM ^{[1
]}

Pasut, G ^{[1
]}

机构：

[1] Univ Padua, Dept Pharmaceut Sci, I-35128 Padua, Italy

来源：

DRUG DISCOVERY TODAY | 2005年 / 10卷 / 21期

关键词：

D O I：

10.1016/S1359-6446(05)03575-0

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

PEGylation defines the modification of a protein, peptide or non-peptide molecule by the linking of one or more polyethylene glycol (PEG) chains. This polymer is nontoxic, non-immunogenic, non-antigenic, highly soluble in water and FDA approved. The PEG-drug conjugates have several advantages: a prolonged residence in body, a decreased degradation by metabolic enzymes and a reduction or elimination of protein immunogenicity. Thanks to these favorable properties, PEGylation now plays an important role in drug delivery, enhancing the potentials of peptides and proteins as therapeutic agents.

引用

页码：1451 / 1458

页数：8

共 49 条

[41] Functionalization of tumor necrosis factor-α using phage display technique and PEGylation improves its antitumor therapeutic window [J].

Shibata, H ;

Yoshioka, Y ;

Ikemizu, S ;

Kobayashi, K ;

Yamamoto, Y ;

Mukai, Y ;

Okamoto, T ;

Taniai, M ;

Kawamura, M ;

Abe, Y ;

Nakagawa, S ;

Hayakawa, T ;

Nagata, S ;

Yamagata, Y ;

Mayumi, T ;

Kamada, H ;

Tsutsumi, Y .

CLINICAL CANCER RESEARCH, 2004, 10 (24) :8293-8300

[42] Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant [J].

Trainer, PJ ;

Drake, WM ;

Katznelson, L ;

Freda, PU ;

Herman-Bonert, V ;

van der Lely, AJ ;

Dimaraki, EV ;

Stewart, PM ;

Friend, KE ;

Vance, ML ;

Besser, GM ;

Scarlett, JA ;

Thorner, MO ;

Parkinson, C ;

Klibanski, A ;

Powell, JS ;

Barkan, AL ;

Sheppard, MC ;

Maldonado, M ;

Rose, DR ;

Clemmons, DR ;

Johannson, G ;

Bengtsson, BÅ ;

Stavrou, S ;

Kleinberg, DL ;

Cook, DM ;

Phillips, LS ;

Bidlingmaier, M ;

Strasburger, CJ ;

Hackett, S ;

Zib, K ;

Bennett, WF ;

Davis, RJ .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (16) :1171-1177

[43]

VARKI A, 1999, ESSENTIAL GLYCOBIOLO

[44] Highly efficient technetium-99m labeling procedure based on the conjugation of N-[N-(3-diphenylphosphinopropionyl)glycyl]cysteine ligand with poly(ethylene glycol) [J].

Visentin, R ;

Pasut, G ;

Veronese, FM ;

Mazzi, U .

BIOCONJUGATE CHEMISTRY, 2004, 15 (05) :1046-1054

[45] Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications [J].

Wang, YS ;

Youngster, S ;

Grace, M ;

Bausch, J ;

Bordens, R ;

Wyss, DF .

ADVANCED DRUG DELIVERY REVIEWS, 2002, 54 (04) :547-570

[46] Poly(ethylene glycol)-conjugated anti-EGF receptor antibody C225 with radiometal chelator attached to the termini of polymer chains [J].

Wen, XX ;

Wu, QP ;

Lu, Y ;

Fan, Z ;

Charnsangavej, C ;

Wallace, S ;

Chow, D ;

Li, C .

BIOCONJUGATE CHEMISTRY, 2001, 12 (04) :545-553

[47]

Wong S.S., 1991, CHEM PROTEIN CONJUGA, P13

[48]

Wood A, 2004, ADV PROTEIN CHEM, V67, P201

[49] Optimal site-specific PEGylation of mutant TNF-α improves its antitumor potency [J].

Yoshioka, Y ;

Tsutsumi, Y ;

Ikemizu, S ;

Yamamoto, Y ;

Shibata, H ;

Nishibata, T ;

Mukai, Y ;

Okamoto, T ;

Taniai, M ;

Kawamura, M ;

Abe, Y ;

Nakagawa, S ;

Nagata, S ;

Yamagata, Y ;

Mayumi, T .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2004, 315 (04) :808-814

← 1 2 3 4 5 →